Erythromycin detailed information

Jump to navigation Jump to search
Erythromycin detailed information
Clinical data
  • AU: A
  • US: B (No risk in non-human studies)
Routes of
oral, iv, im
ATC code
Legal status
Legal status
Pharmacokinetic data
Protein binding90%
Metabolismliver (under 5% excreted unchanged)
Elimination half-life1.5 hours
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass733.93 g/mol

WikiDoc Resources for Erythromycin detailed information


Most recent articles on Erythromycin detailed information

Most cited articles on Erythromycin detailed information

Review articles on Erythromycin detailed information

Articles on Erythromycin detailed information in N Eng J Med, Lancet, BMJ


Powerpoint slides on Erythromycin detailed information

Images of Erythromycin detailed information

Photos of Erythromycin detailed information

Podcasts & MP3s on Erythromycin detailed information

Videos on Erythromycin detailed information

Evidence Based Medicine

Cochrane Collaboration on Erythromycin detailed information

Bandolier on Erythromycin detailed information

TRIP on Erythromycin detailed information

Clinical Trials

Ongoing Trials on Erythromycin detailed information at Clinical

Trial results on Erythromycin detailed information

Clinical Trials on Erythromycin detailed information at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Erythromycin detailed information

NICE Guidance on Erythromycin detailed information


FDA on Erythromycin detailed information

CDC on Erythromycin detailed information


Books on Erythromycin detailed information


Erythromycin detailed information in the news

Be alerted to news on Erythromycin detailed information

News trends on Erythromycin detailed information


Blogs on Erythromycin detailed information


Definitions of Erythromycin detailed information

Patient Resources / Community

Patient resources on Erythromycin detailed information

Discussion groups on Erythromycin detailed information

Patient Handouts on Erythromycin detailed information

Directions to Hospitals Treating Erythromycin detailed information

Risk calculators and risk factors for Erythromycin detailed information

Healthcare Provider Resources

Symptoms of Erythromycin detailed information

Causes & Risk Factors for Erythromycin detailed information

Diagnostic studies for Erythromycin detailed information

Treatment of Erythromycin detailed information

Continuing Medical Education (CME)

CME Programs on Erythromycin detailed information


Erythromycin detailed information en Espanol

Erythromycin detailed information en Francais


Erythromycin detailed information in the Marketplace

Patents on Erythromycin detailed information

Experimental / Informatics

List of terms related to Erythromycin detailed information

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Erythromycin is a macrolide antibiotic that has an antimicrobial spectrum similar to or slightly wider than that of penicillin, and is often used for people that have an allergy to penicillins. For respiratory tract infections, it has better coverage of atypical organisms, including mycoplasma and Legionellosis. It is also used to treat outbreaks of chlamydia, syphilis, acne, and gonorrhea. In structure, this macrocyclic compound contains a 14-membered lactone ring with ten asymmetric centers and two sugars (L-cladinose and D-desoamine), making it a compound very difficult to produce via synthetic methods.

Erythromycin is produced from a strain of the actinomycete Saccharopolyspora erythraea, formerly known as Streptomyces erythraeus.


Abelardo Aguilar, a Filipino scientist, sent some soil samples to his employer Eli Lilly in 1949. Eli Lilly’s research team, led by J. M. McGuire, managed to isolate Erythromycin from the metabolic products of a strain of Streptomyces erythreus (designation changed to "Saccharopolyspora erythraea") found in the samples.

Lilly filed for patent protection of the compound and U.S. patent 2,653,899 was granted in 1953. The product was launched commercially in 1952 under the brand name Ilosone (after the Philippine region of Iloilo where it was originally collected from). Erythromycin was formerly also called Ilotycin.

In 1981, Nobel laureate (1965 in chemistry) and Professor of Chemistry at Harvard University (Cambridge, MA) Robert B. Woodward, along with a large number of members from his research group, posthumously reported the first stereocontrolled asymmetric chemical synthesis of Erythromycin A.

The antiobiotic clarithromycin was invented by scientists at the Japanese drug company Taisho Pharmaceutical in the 1970s as a result of their efforts to overcome the acid instability of erythromycin.

Available Forms

Erythromycin is available in enteric-coated tablets, slow-release capsules, oral suspensions, ophthalmic solutions, ointments, gels, and injections.

Brand names include Robimycin, E-Mycin, E.E.S. Granules, E.E.S.-200, E.E.S.-400, E.E.S.-400 Filmtab, Erymax, Ery-Tab, Eryc, Erypar, EryPed, Eryped 200, Eryped 400, Erythrocin Stearate Filmtab, Erythrocot, E-Base, Erythroped, Ilosone, MY-E, Pediamycin, Zineryt, Abboticin, Abboticin-ES, Erycin, PCE Dispertab, Stiemycine and Acnasol.

Mechanism of action

Erythromycin may possess bacteriocidal activity, particularly at higher concentrations[1]. The mechanism is not fully elucidated however. By binding to the 50S subunit of the bacterial 70S rRNA complex, protein synthesis and subsequently structure/function processes critical for life or replication are inhibited[2]. Erythromycin interferes with aminoacyl translocation, preventing the transfer of the tRNA bound at the A site of the rRNA complex to the P site of the rRNA complex. Without this translocation, the A site remains occupied and thus the addition of an incoming tRNA and its attached amino acid to the nascent polypeptide chain is inhibited. This interferes with the production of functionally useful proteins and is therefore the basis of antimicrobial action.


Erythromycin is easily inactivated by gastric acid; therefore, all orally-administered formulations are given as either enteric-coated or more-stable laxatives or esters, such as erythromycin ethylsuccinate. Erythromycin is very rapidly absorbed, and diffuses into most tissues and phagocytes. Due to the high concentration in phagocytes, erythromycin is actively transported to the site of infection, where, during active phagocytosis, large concentrations of erythromycin are released.


Most of erythromycin is metabolised by demethylation in the liver. Its main elimination route is in the bile, and a small portion in the urine. Erythromycin's elimination half-life is 1.5 hours.

Adverse effects

Erythromycin inhibits the cytochrome P450 system, particularly CYP3A4, which can cause it to affect the metabolism of many different drugs. If CYP3A4 substrates, such as simvastatin (Zocor), lovastatin (Mevacor), or atorvastatin (Lipitor), are taken concomitantly with erythromycin, levels of the substrates will increase, often causing adverse effects. A noted drug interaction involves erythromycin and simvastatin, resulting in increased simvastatin levels and the potential for rhabdomyolysis.

Gastrointestinal disturbances, such as diarrhea, nausea, abdominal pain, and vomiting, are fairly common, so erythromycin tends not to be prescribed as a first-line drug. However, erythromycin may be useful in treating gastroparesis due to this pro-motility effect. Intravenous erythromycin may also be used in endoscopy as an adjunct to clear gastric contents.

More serious side-effects, such as arrhythmia and reversible deafness, are rare. Allergic reactions, while uncommon, may occur, ranging from urticaria to anaphylaxis. Cholestasis, Stevens-Johnson syndrome, and toxic epidermal necrolysis are some other rare side-effects that may occur.

Erythromycin has been shown to increase the probability of pyloric stenosis in children whose mothers took the drug during the late stages of pregnancy or while nursing.

It can also cause hyperactivity in high doses.


Earlier case reports on sudden death prompted a study on a large cohort that confirmed a link between erythromycin, ventricular tachycardia, and sudden cardiac death in patients also taking drugs that prolong the metabolism of erythromycin (like verapamil or diltiazem) by interfering with CYP3A4 (Ray et al 2004). Hence, erythromycin should not be administered in patients using these drugs, or drugs that also prolong the QT time. Other examples include terfenadine (Seldane, Seldane-D), astemizole (Hismanal), cisapride (Propulsid, withdrawn in many countries for prolonging the QT time) and pimozide (Orap).


  1. Katzung PHARMACOLOGY, 9e Section VIII. Chemotherapeutic Drugs Chapter 44. Chloramphenicol, Tetracyclines, Macrolides, Clindamycin, & Streptogramins
  2. Katzung PHARMACOLOGY, 9e Section VIII. Chemotherapeutic Drugs Chapter 44. Chloramphenicol, Tetracyclines, Macrolides, Clindamycin, & Streptogramins

Additional Resources

  • Ray WA, Murray KT, Meredith S, Narasimhulu SS, Hall K, Stein CM. Oral Erythromycin and the Risk of Sudden Death from Cardiac Causes. N Engl J Med 2004;351:1089-96.
  • British National Formulary "BNF 49" March 2005.
  • Mims C, Dockrell HM, Goering RV, Roitt I, Wakelin D, Zuckerman M. Chapter 33: Attacking the Enemy: Antimicrobial Agents and Chemotherapy: Macrolides. In: Medical Microbiology (3rd Edition). London: Mosby Ltd; 2004. p 489

External links


ar:إرثرومايسن de:Erythromycin fa:آزیترومایسین it:Eritromicina hu:Eritromicin nl:Erytromycine no:Erytromycin nn:Erythromycin oc:Eritromicina fi:Erytromysiini sv:Erytromycin th:อิริโทรมัยซิน


Template:WikiDoc Sources